Market Place
Sourcing Support
Zevra to Present Data on Niemann-Pick Disease Type C at CNS
11 Nov 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Attend Guggenheim Healthcare Conference
06 Nov 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Report Q3 2024 Results on Nov 12, 2024
31 Oct 2024 //
GLOBENEWSWIRE
Zevra, nonprofit team up to drive diagnosis of rare diseases
10 Oct 2024 //
FIERCE PHARMA
Zevra Joins Rare Disease Panel At 2024 Maxim Healthcare Summit
10 Oct 2024 //
GLOBENEWSWIRE
NUCDF And Zevra Launch Check Ammonia Campaign For Disorders
09 Oct 2024 //
GLOBENEWSWIRE
IntraBio hits the ground running with new rare disease launch
30 Sep 2024 //
FIERCE PHARMA
Orsini Named Exclusive Specialty Pharmacy for MIPLYFFA™ in U.S.
24 Sep 2024 //
PR NEWSWIRE
Zevra Therapeutics to Present KP1077 Data at Sleep Europe 2024
24 Sep 2024 //
GLOBENEWSWIRE
Zevra Prices Rare Disorder Drug At Up To $106,000 Per Month
23 Sep 2024 //
REUTERS
FDA Approves First Treatment for Niemann-Pick Disease, Type C
23 Sep 2024 //
PRNEWSWIRE
Relief Therapeutics Announces $2 Million Milestone
20 Sep 2024 //
ACCESSWIRE
Zevra Presents New Data On Arimoclomol And OLPRUVA At SSIEM Symposium
06 Sep 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Participate at Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Reports Q2 2024 Results And Corporate Highlights
13 Aug 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
09 Aug 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Announces Proposed Public Offering of Common Stock
08 Aug 2024 //
GLOBENEWSWIRE
Zevra Therapeutics To Present At Canaccord Genuity Growth Conference
07 Aug 2024 //
GLOBENEWSWIRE
Clinical intuition` led FDA advisors to back Zevra`s rare disease med
05 Aug 2024 //
FIERCE BIOTECH
FDA Panel Votes Favorably On Arimoclomol For Niemann-Pick Disease Type C
02 Aug 2024 //
GLOBENEWSWIRE
FDA Questions Evidence For Zevra`s Rare Disease Therapy Pre-Adcomm
02 Aug 2024 //
BIOSPACE
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
30 Jul 2024 //
GLOBENEWSWIRE
Zevra Announces FDA Meeting To Review Arimoclomol For Niemann-Pick
09 Jul 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Expands Executive Leadership Team
25 Jun 2024 //
GLOBENEWSWIRE
Zevra Transitions To Orsini As Provider For OLPRUVA® In Urea Cycle Disorders
18 Jun 2024 //
GLOBENEWSWIRE
Zevra`s KP1077 Shows Positive Phase 2 Results In Idiopathic Hypersomnia
03 Jun 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Participate at Upcoming Investor Events
09 May 2024 //
GLOBENEWSWIRE
Zevra Q1 2024 Financials, Corporate Updates
08 May 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
01 May 2024 //
GLOBENEWSWIRE
Zevra CEO`s Shareholder Letter on 2023 Progress & 2024 Outlook
29 Apr 2024 //
GLOBENEWSWIRE
Zevra: Arimoclomol Long-Term NPC Safety, Efficacy At SIMD
15 Apr 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Refinances Debt, Secures Up to $100M Capital
10 Apr 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Zevra Announces Top-Line Data from the Phase 2 Trial of KP1077 for IH
26 Mar 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Conference
25 Mar 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results
18 Mar 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol
04 Mar 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Participate at Upcoming Investor Conferences
28 Feb 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Conference
06 Feb 2024 //
GLOBENEWSWIRE
Zevra Appoints Biopharma Executive Alvin Shih to the Board of Directors
23 Jan 2024 //
GLOBENEWSWIRE
Zevra Receives FDA Acceptance of Resubmission of NDA for Arimoclomol
08 Jan 2024 //
GLOBENEWSWIRE
Zevra Appoints Global Medical Leader, Adrian Quartel as Chief Medical Officer
04 Jan 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Announces Resubmission of Arimoclomol NDA to FDA
27 Dec 2023 //
GLOBENEWSWIRE
Zevra Therapeutics Acquires Acer Therapeutics
20 Nov 2023 //
CONTRACT PHARMA
Zevra Therapeutics Completes Acquisition of Acer Therapeutics
20 Nov 2023 //
GLOBENEWSWIRE
Zevra Reports Corporate Updates and Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Zevra to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET
31 Oct 2023 //
GLOBENEWSWIRE
Zevra Celebrates and Supports Global Niemann-Pick Disease Awareness Day
19 Oct 2023 //
GLOBENEWSWIRE
Zevra Appoints Neil F. McFarlane as President, Chief Executive Officer
10 Oct 2023 //
GLOBENEWSWIRE
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
05 Oct 2023 //
GLOBENEWSWIRE
Zevra Announces Interim Data from the Phase 2 Clinical Trial of KP1077
02 Oct 2023 //
GLOBENEWSWIRE
Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference
20 Sep 2023 //
GLOBENEWSWIRE
Zevra to Participate in H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
Zevra Acquires Acer for $91M
31 Aug 2023 //
CONTRACT PHARMA
Zevra Reports Corporate Updates and Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Zevra Therapeutics Appoints Thomas Anderson to Board of Directors
07 Aug 2023 //
GLOBENEWSWIRE
Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023
02 Aug 2023 //
GLOBENEWSWIRE
Zevra to Participate in the 2023 NNPDF Family Support and Medical Conference
19 Jul 2023 //
GLOBENEWSWIRE
Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes
20 Jun 2023 //
GLOBENEWSWIRE
Zevra to Participate in the Healthcare Conference Presented by Maxim Group
13 Jun 2023 //
GLOBENEWSWIRE
